{"@id":"https://bioecon.ru/technology/tcr-immune-receptor-therapies/","@type":"Technology","cluster":"regenerative-personalized","formats":{"html":"https://en.bioecon.ru/technology/tcr-immune-receptor-therapies/","json":"https://en.bioecon.ru/api/v1/technology/tcr-immune-receptor-therapies/index.json"},"id":"tcr-immune-receptor-therapies","industries":["pharma","biomanufacturing"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/cryoport-systems/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/quantec-ltd/","https://bioecon.ru/companies/minicircle/","https://bioecon.ru/companies/anft-association-of-nature-forest-therapy/","https://bioecon.ru/companies/kheiron-biotech/","https://bioecon.ru/companies/pbs-biotech/","https://bioecon.ru/companies/retro-biosciences/"]},"maturity":7,"name":"TCR and Immune Receptor Therapies","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Intracellular epitope identification"},{"n":2,"title":"Structure-guided TCR affinity tuning"},{"n":3,"title":"Endogenous TCR gene deletion"},{"n":4,"title":"Coronin 1 signaling modulation"}],"summary":"Engineering high-affinity T-cell receptor (TCR) alpha/beta heterodimers targeting intracellular oncogenic peptides presented on human leukocyte antigens (HLA), combined with coronin 1 pathway modulation to govern graft tolerance and autoimmunity.","url":"/technology/tcr-immune-receptor-therapies/","verified":"2026-11-22"}